Ligand Pharmaceuticals
LGND
196 hedge funds and large institutions have $947M invested in Ligand Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 67 increasing their positions, 77 reducing their positions, and 27 closing their positions.
126% more call options, than puts
Call options by funds: $5.38M | Put options by funds: $2.38M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 90.2% → 90.13% (-0.07%)
4% less funds holding
Funds holding: 204 → 196 (-8)
13% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 77
16% less capital invested
Capital invested by funds: $1.12B → $947M (-$177M)
26% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$10.2M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.46M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$4.47M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.58M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$9.62M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$4.52M |
| 3 |
BlackRock
New York
|
-$4.28M |
| 4 |
CC
Chicago Capital
Chicago,
Illinois
|
-$4.19M |
| 5 |
BC
Burney Company
Reston,
Virginia
|
-$3.75M |
LGND Hedge Fund Activity: Q3 2023 in Review
196 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2023, worth a combined $947M — down 16% from $1.12B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of LGND and 20 opened new positions — a net loss of 7 holders — while 77 trimmed existing stakes and 67 added.
The largest buyer was Macquarie Group, adding an estimated $10.2M. The largest seller was Man Group, exiting entirely with an estimated $9.62M sold.
- 196 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2023, down from 204 in Q2 2023.
- Funds reported $947M of Ligand Pharmaceuticals stock for Q3 2023, down 16% quarter-over-quarter.
- 20 funds opened new Ligand Pharmaceuticals positions in Q3 2023 and 27 closed out, a net change of -7 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2023 was Macquarie Group, an estimated $10.2M added.
- The largest Ligand Pharmaceuticals seller in Q3 2023 was Man Group, an estimated $9.62M sold.
Based on aggregated 13F filings for Q3 2023.